Tay-Sachs disease destroys nerve cells in the brain and spinal cord by flooding them with a fatty substance they can’t break down. In its most common form, which appears in infancy, it causes a child to lose the ability to move, see, and hear, and is fatal within a few years. Rarer forms can appear in childhood or adulthood with a slower but still serious progression.
How the Disease Damages Nerve Cells
Your cells contain tiny recycling centers called lysosomes, which break down waste materials so they don’t accumulate. One of the substances lysosomes handle is GM2 ganglioside, a fatty molecule found in cell membranes throughout the nervous system. To break it down, your body needs an enzyme called beta-hexosaminidase A, which is built from instructions in a gene called HEXA.
In Tay-Sachs disease, mutations in the HEXA gene eliminate or severely reduce the activity of this enzyme. Without it, GM2 ganglioside piles up inside neurons to toxic levels. The buildup progressively damages and eventually destroys those nerve cells. Because ganglioside is especially concentrated in the brain and spinal cord, the nervous system takes the hardest hit.
What Happens in Infantile Tay-Sachs
The infantile form is the most common and most severe. Babies typically appear healthy at birth, with symptoms first showing up between 3 and 6 months of age. Parents often notice that their baby stops reaching developmental milestones or begins losing skills they had already gained, like rolling over, crawling, or sitting up.
As the disease progresses, muscles weaken significantly. Seizures begin. Vision and hearing deteriorate and are eventually lost. One of the hallmark signs, present in roughly 90% of affected infants, is a cherry-red spot visible on an eye exam. This spot appears because ganglioside accumulates in the retinal nerve cells surrounding the fovea (the center of the retina), turning the surrounding tissue pale and opaque. The fovea itself has no nerve cell layer, so the normal red color of the tissue beneath shows through by contrast.
Children with this form of Tay-Sachs typically survive only a few years. The most common cause of death is respiratory infection, because weakened muscles make it difficult to clear mucus from the airways or breathe effectively.
Juvenile and Adult-Onset Forms
Not all Tay-Sachs mutations shut down the enzyme completely. Some leave a small amount of residual activity, which slows the buildup of ganglioside and delays the onset of symptoms.
The juvenile form typically appears in early childhood. Children develop problems with coordination, difficulty speaking, and trouble swallowing. Muscle stiffness increases over time. Unlike the infantile form, a cherry-red spot is not always present. Optic nerve damage and vision changes can develop later. By ages 10 to 15, children with this form generally reach a vegetative state, with death following within a few years, often from respiratory complications.
Late-onset Tay-Sachs (LOTS) can appear anytime from adolescence into adulthood. Its symptoms look quite different from the infantile form and can be difficult to diagnose. Initial signs may include muscle weakness, problems with balance and coordination, slurred speech, or tremor. Some people first present with psychiatric symptoms, including psychosis or treatment-resistant mental health conditions, before neurological signs become obvious. The progression is much slower, but the disease still causes significant disability over time.
How Tay-Sachs Is Inherited
Tay-Sachs follows an autosomal recessive pattern, meaning a child must inherit a defective copy of the HEXA gene from both parents to develop the disease. If both parents are carriers (each carrying one working copy and one faulty copy), there is a 25% chance with each pregnancy that their child will have Tay-Sachs, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit two working copies.
Carrier rates vary dramatically by population. About 1 in 27 Ashkenazi Jews in the United States carries a Tay-Sachs mutation. French Canadians near the St. Lawrence River and Cajun communities in Louisiana also have elevated rates. In the general population, roughly 1 in 250 people is a carrier.
How It’s Diagnosed
Diagnosis relies on two main approaches. The first is an enzyme activity test, which measures how much beta-hexosaminidase A is present in a blood sample. Significantly reduced activity confirms the disease, while below-normal levels indicate carrier status. The second is genetic sequencing of the HEXA gene itself, which can identify the specific mutation responsible. Carrier screening using one or both methods is widely recommended for people in higher-risk populations and is increasingly offered as part of routine preconception genetic panels.
In infants, the cherry-red spot on an eye exam is often the first clinical clue that prompts further testing, especially when paired with developmental regression.
What Care Looks Like
There is currently no cure for Tay-Sachs disease, and no treatment that can reverse or stop the nerve damage once it has occurred. Care focuses on managing symptoms and maintaining comfort.
Respiratory support is a central concern. Because the muscles involved in breathing and coughing weaken, affected children need help keeping their airways clear. This can involve chest physiotherapy, suctioning, and sometimes supplemental oxygen. Respiratory infections require close monitoring and prompt treatment, since they are the leading cause of death.
Seizures are managed to reduce their frequency and severity. Swallowing difficulties often require feeding assistance, and some children eventually need a feeding tube to maintain nutrition and hydration safely. Physical therapy helps maintain muscle tone and joint flexibility for as long as possible.
For adults with late-onset Tay-Sachs, care often includes physical and speech therapy to preserve function, along with treatment for psychiatric symptoms when they arise. Gene therapy trials are underway, with at least one study tracking patients who received a gene therapy called AXO-AAV-GM2 delivered directly to the brain. That trial is currently in long-term follow-up, monitoring participants for five years after treatment, but results are not yet conclusive.